-
Human medicines European public assessment report (EPAR): NeoRecormon, epoetin beta, Date of authorisation: 16/07/1997, Revision: 34, Status: Authorised
22 Jul 2024 18:58 GMT
The types of side effects seen with NeoRecormon depend on the cause of the patient’s anaemia. The most common side effects (seen in between 1 and 10 patients in 100) are hypertension (high blood pressure), headache and thromboembolic events (formation of …
-
Roche partners with Entero Healthcare on nephrology medicines
18 Jun 2020 06:52 GMT
… to improve access to nephrology medicines.
Under this agreement, … nephrology drugs, Mycophenolate Mofetil (Cellcept), Valganciclovir (Valcyte), Epoetin Beta (NeoRecormon), and …
Or click on Free Trial to get 14 days … free trial.
What You' …
-
Roche Pharma India expands partnership with Cipla for key oncology medicines
18 Jun 2020 06:23 GMT
… to its key oncology medicines in India.
Roche … of its trademark oncology drugs - trastuzumab (Herclon), … improve access to nephrology medicines in India.
Under … drugs such as mycophenolate mofetil (Cellcept), valganciclovir (Valcyte), epoetin beta (NeoRecormon …
-
An economist’s perspective on abuse of dominance and killer acquisitions in the pharma industry
14 Aug 2024 12:58 GMT
… drugs, biosimilar drugs are ‘similar to’ the originator biological medicine … generic challenger, for treatment of opiate addiction … Portugal)
Roche
NeoRecormon and Aranesp, prescription pharmaceuticals restricted to … the companies offered remedies to ensure that …
-
Injectable Hematology Growth Factors Report 2024 - Evolution in Therapeutic Care - ResearchAndMarkets.com
13 Feb 2024 12:11 GMT
… of Biological Drugs
Product Manufacturers
…
Grastofil
Mircera
NeoRecormon
Neulasta
Neupogen
… Medice Arzneimittel
Mylan International
Novartis
Pfizer
Ratiopharm
Rentscler Biotechnologie …
Roche
Sandoz
Stada Arzneimittel AG
Teva Pharmaceuticals …
-
Global Erythropoietin Market Research Consumption, Market Size, Companies , Industry Report Analysis And Future Demand And Forecast: 2022-2031
25 Aug 2022 10:09 GMT
… NeoRecormon, created by F. Hoffman-La Roche, is the primary medication … drug, Epogen was endorsed by the U.S. FDA for the treatment … the treatment of frailty. Significant remedial exploration … ; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd …
-
Global Erythropoietin Market Size 2022 Industry Share, Business Strategies, Growth Analysis, Regional Demand, Revenue, Key Manufacturers And 2031 Forecast Research Report
13 Jul 2022 07:35 GMT
… NeoRecormon, created by F. Hoffman-La Roche, is the primary medication … drug, Epogen was endorsed by the U.S. FDA for the treatment … the treatment of frailty. Significant remedial exploration … ; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd …
About
© 1995-2025